BenevolentAI SPAC Presentation Deck

BEN-8744 results and progress to date 2020 Target validation 2019 Novel, potent advanced lead molecule developed within 2 years TARGET IDENTIFICATION Novel target for UC ✓ Discovered using Benevolent TargetID tools PDE10 has zero linkage to UC in all available biomedical literature ✓ Experimentally validated in ex-vivo UC colon samples from patients refractory to SoC treatment 2021 CHEMISTRY Candidate nomination Rapid and efficient lead optimisation ✓ Molecular Design tools enabled rapid and efficient lead optimisation ✔ Candidate nominated in Sep '21 Novel, potent, selective, peripherally restricted PDE10. Inhibitor, with low dose prediction ✓ Only 2 years from programme initiation 2022 Preclinical 2023 Phase I clinical study CLINICAL DEVELOPMENT Developing responder and progression endotypes We will develop responder and progression endotypes, adding molecular descriptors These will inform our trial designs, patient selection and target identification in UC Augmenting a further loop of iteration on an enriched graph Benevolent 27

View entire presentation